Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer

Background: Despite remarkable success of immunotherapies with checkpoint blockade antibodies targeting programmed cell death protein 1 (PD-1), the majority of patients with non-small-cell lung cancer (NSCLC) have yet to receive durable benefits. We used the metabolomic profiling of early on-treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Xiaoqun, Xia, Liliang, Gao, Fang, Liu, Lixia, Yang, Yi, Chen, Yingying, Duan, Huangqi, Yao, Yaxian, Chen, Zhiwei, Lu, Shun, Wang, Ying, Yang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176105/
https://www.ncbi.nlm.nih.gov/pubmed/34095230
http://dx.doi.org/10.3389/fmolb.2021.678753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176105/
https://www.ncbi.nlm.nih.gov/pubmed/34095230
http://dx.doi.org/10.3389/fmolb.2021.678753

Ejemplares similares